Clinical Trials Browser

Phase 1 × Triple Negative Breast Neoplasms × eribulin × Clear all

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02616848 2015-11-30

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Phase 1 Unknown

Triple Negative Breast Neoplasms